Latest from MSKCC

Komal L. Jhaveri, MD, FACP, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses acquired resistance to CDK 4/6 inhibitors in breast cancer.

Anas Younes, MD, discusses the current and future state of CAR T-cell therapies and immune checkpoint inhibitors in the landscape of hematologic malignancies.

Robert J. Motzer, MD, has been at the forefront of research into renal cell carcinoma for nearly 30 years, with his work contributing to the approval of at least 8 new drugs. 

Matthew D. Hellmann, MD, assistant attending physician, Memorial Sloan Kettering Cancer Center, discusses the process of tumor mutational burden (TMB) testing in patients with lung cancer.

Paul K. Paik, MD, clinical director of the Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, discusses how the potential approval of lorlatinib may alter the landscape for patients with ALK-positive non–small cell lung cancer (NSCLC).

Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses targets for chimeric antigen receptor (CAR) T-cell therapy.
 

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the FDA approval of dabrafenib (Tafinlar) plus trametinib (Mekinist) as an adjuvant treatment for patients with BRAF V600E– or V600K–positive stage III melanoma following complete resection.

Carboxyamidotriazole orotate in combination with temozolomide, with or without radiotherapy, produced positive safety and efficacy results in a phase Ib study of patients with glioblastoma or anaplastic gliomas.